To Determine the MTD and to Evaluate the Safety, Efficacy and PK Profiles of TSB-9-W1 in Pre-treated Patients With mCRC.

NCT02249650 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: TSB-9-W1

Sponsor

Taiwan Sunpan Biotechnology Development Co., Ltd.

Collaborators

[object Object]